ArticleBMC cancer2026
Network-based integrative transcriptomic analysis reveals immune-regulatory and oncogenic signatures of EOMES and SPRYD3 in head and neck squamous cell carcinoma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHead and neck squamous cell carcinoma (HNSCC) exhibits marked heterogeneity driven by both tumor-intrinsic programs and immune context. However, the relationship between epithelial proliferation and immune activity remains incompletely defined.
methodsWe combined bulk transcriptomic analyses of HNSCC cohorts (GSE83519 and TCGA-HNSC) with single-cell RNA sequencing data derived from OSCC (GSE172577) to identify gene programs associated with tumor progression. Co-expression network analysis was used to identify tumor-related modules, and candidate genes were evaluated by survival analysis and experimental validation. Single-cell analysis of an OSCC cohort and CopyKAT-based epithelial cell identification were performed to define cell-type-specific expression patterns.
resultsEOMES and SPRYD3 were identified as candidate prognostic markers associated with distinct biological programs. Single-cell analysis showed that SPRYD3 expression was enriched in aneuploid epithelial cells, whereas EOMES expression was restricted to cytotoxic lymphocyte populations. Tumor epithelial cells with high SPRYD3 expression exhibited activation of cell cycle and DNA replication pathways, while immune-related signaling was reduced. In contrast, EOMES expression was associated with interferon response and T-cell effector programs. Experimental validation supported increased SPRYD3 expression, whereas EOMES exhibited a tendency toward lower expression in OSCC tissues.
conclusionsSPRYD3 and EOMES represent distinct transcriptional programs associated with epithelial proliferation and immune activity in HNSCC. These findings provide a framework for understanding tumor-immune interactions and highlight the potential prognostic and biological relevance of EOMES and SPRYD3 in HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.